Moorfields Eye Hospital
London, EC1V 2PD, United Kingdom
NCT Number: NCT01983488
This study is aimed at investigating the long term clinical outcome of patients with uveitis.
Looking for future studies?
Notify MeAll sexes
Observational
London, EC1V 2PD, United Kingdom
Patients will be included if they are treated for uveitis and have had repeat follow-up. Data will be gathered from the entire length of the patients follow-up.
The main outcome measures will be:
Change from baseline of Best corrected visual acuity (BCVA)at 10 years Causes of vision loss (≤6/15, VL) and severe vision loss (≤6/60, SVL) at 10 years Number of clinical visits at 10 years.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: up to 10 years
Recorded repeat best corrected visual acuity at intervals throughout the length of follow-up.
Time frame: First follow-up, years 1,2,5,10, Final follow-up
Record any ocular changes related to permanent visual loss under 6/12 and severe visual loss under 6/60.
Looking for future studies?
Notify MeMoorfields Eye Hospital NHS Foundation Trust
Other
Clinical Outcome and Causes of Visual Loss in Uveitis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05727540
Eye Diseases, Uveal Diseases
Guangzhou, Guangdong, China
View Trial DetailsNCT01859299
Eye Diseases, Uveal Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT06310837
Eye Diseases, Uveal Diseases
Shenzhen, Guangdong, China
View Trial DetailsNCT05388838
Eye Diseases, Hemic and Lymphatic Diseases
Lyon, France
View Trial Details